BlockBeats News, October 9th, Biotechnology company Leap Therapeutics (NASDAQ: LPTX), focused on developing targeted and immune-boosting cancer therapies, announced today that it has completed the previously announced private placement transaction. The financing was led by Winklevoss Capital, raising a total of $58,888,888 in cash to launch the company’s Digital Asset Treasury strategy.
At the time of the transaction’s completion, Leap issued the following securities to investors:
(i) 15,212,311 shares of common stock (“Common Stock”);
(ii) pre-subscription warrants entitling the purchase of a total of 80,768,504 shares of Common Stock (“Pre-Warrants”);
(iii) and warrants to purchase 71,985,605 shares of Common Stock at an exercise price of $0.5335 per share (“Warrants,” collectively referred to as “Units” with Common Stock and Pre-Warrants).
Winklevoss Capital will provide funding and strategic support to Leap to assist in designing and implementing the Digital Asset Treasury strategy. Leveraging Winklevoss Capital’s expertise, Leap aims to create long-term value for shareholders through involvement in the digital asset space. Some of the financing proceeds will also be used to advance the company’s therapeutic projects, including FL-501 and Sirexatamab. The latter recently completed a randomized controlled Phase II clinical trial for colorectal cancer patients and will be presented in a Mini Oral Session on October 19, 2025, at the European Society for Medical Oncology (ESMO) Congress in Berlin, Germany.
